Literature DB >> 21725797

Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke.

Li Ran1, Nikan H Khatibi, Xinyue Qin, John H Zhang.   

Abstract

BACKGROUND: Stress-related mucosal damage is an erosive process of the gastric lining resulting from abnormally high physiologic demands. To avoid the morbidity and mortality associated with significant bleeding from the damage, prophylaxis with an acid suppression medication is given. This is especially common in stroke victims. Recent studies have suggested a link between acid suppression therapy and nosocomial pneumonia, specifically implicating proton pump inhibitors (PPI), a potent acid suppression medication, as the culprit. In this retrospective study, we reviewed the medical records of admitted intracerebral hemorrhage (ICH) patients and determined if there is a link between PPI prophylaxis and nosocomial pneumonia in our ICH population.
MATERIALS AND METHODS: Medical records of 200 ICH patients admitted to the First Affiliated Hospital of Chongqing Medical University were reviewed from January 1, 2008 to October 31, 2009. PPIs were the only accepted form of acid suppression therapy. In all, 95 patients were given PPI prophylaxis, whereas 105 patients did not receive any form of acid suppression.
RESULTS: The unadjusted incidence rate of pneumonia in the PPI prophylactic group was 23.2%, and 10.5% in patients not having received prophylaxis. Additionally, patients treated with PPI prophylaxis were more likely to be critically ill, defined by an increase in conscious disturbance and dependency on mechanical ventilation and/or a nasogastric tube.
CONCLUSION: The use of a PPI as a prophylactic treatment against stress-related mucosal damage was associated with a higher occurrence of nosocomial pneumonia in our ICH population. This study suggests the need for further research investigating the use of PPI prophylaxis in ICH patients and the possibility of using alternate acid suppression therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725797     DOI: 10.1007/978-3-7091-0693-8_75

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  7 in total

Review 1.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 2.  Stress Ulcer Prophylaxis in Neurocritical Care.

Authors:  Jeffrey F Barletta; Alicia J Mangram; Joseph F Sucher; Victor Zach
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

3.  Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia.

Authors:  Shoshana J Herzig; Christopher Doughty; Sourabh Lahoti; Sarah Marchina; Neha Sanan; Wuwei Feng; Sandeep Kumar
Journal:  Ann Neurol       Date:  2014-09-17       Impact factor: 10.422

4.  Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors.

Authors:  Sai-Wai Ho; Ming-Che Tsai; Ying-Hock Teng; Ying-Tung Yeh; Yu-Hsun Wang; Shun-Fa Yang; Chao-Bin Yeh
Journal:  BMJ Open       Date:  2014-11-10       Impact factor: 2.692

5.  Mortality is associated with inflammation, anemia, specific diseases and treatments, and molecular markers.

Authors:  Mark Moeller; Christiane Pink; Nicole Endlich; Karlhans Endlich; Hans-Jörgen Grabe; Henry Völzke; Marcus Dörr; Matthias Nauck; Markus M Lerch; Rüdiger Köhling; Birte Holtfreter; Thomas Kocher; Georg Fuellen
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

6.  Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.

Authors:  Tae-Jin Song; Jinkwon Kim
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.240

7.  Risk of Stroke-Associated Pneumonia With Acid-Suppressive Drugs: A Population-Based Cohort Study.

Authors:  Sai-Wai Ho; Ming-Ju Hsieh; Shun-Fa Yang; Ying-Tung Yeh; Yu-Hsun Wang; Chao-Bin Yeh
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.